| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
46,330 |
34,671 |
$4.42M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
535 |
429 |
$459.29 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
23,527 |
18,168 |
$72.84 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
377 |
308 |
$0.00 |
| 81025 |
|
565 |
446 |
$0.00 |
| 81003 |
|
1,070 |
889 |
$0.00 |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,365 |
1,928 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,997 |
2,203 |
$0.00 |
| 80061 |
Lipid panel |
1,792 |
1,571 |
$0.00 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
260 |
245 |
$0.00 |
| 3078F |
|
845 |
769 |
$0.00 |
| 99201 |
|
209 |
165 |
$0.00 |
| 99307 |
|
796 |
547 |
$0.00 |
| 3077F |
|
208 |
196 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
148 |
92 |
$0.00 |
| 80346 |
|
28 |
28 |
$0.00 |
| 80348 |
|
132 |
84 |
$0.00 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
331 |
230 |
$0.00 |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
49 |
37 |
$0.00 |
| 80354 |
|
34 |
25 |
$0.00 |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
39 |
30 |
$0.00 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
64 |
45 |
$0.00 |
| 99173 |
|
17 |
16 |
$0.00 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
38 |
25 |
$0.00 |
| 80074 |
|
17 |
12 |
$0.00 |
| 80053 |
Comprehensive metabolic panel |
3,996 |
3,463 |
$0.00 |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,648 |
1,436 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,393 |
2,847 |
$0.00 |
| 36415 |
Collection of venous blood by venipuncture |
4,050 |
3,579 |
$0.00 |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
35 |
29 |
$0.00 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,529 |
2,991 |
$0.00 |
| 87428 |
|
874 |
816 |
$0.00 |
| 83735 |
|
941 |
829 |
$0.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
475 |
389 |
$0.00 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
1,071 |
958 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
141 |
129 |
$0.00 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
160 |
139 |
$0.00 |
| 3080F |
|
206 |
195 |
$0.00 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
507 |
475 |
$0.00 |
| 3074F |
|
849 |
773 |
$0.00 |
| 90686 |
|
221 |
181 |
$0.00 |
| 80349 |
|
33 |
24 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
127 |
78 |
$0.00 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
15 |
15 |
$0.00 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
39 |
26 |
$0.00 |
| 90688 |
|
46 |
27 |
$0.00 |
| 81001 |
|
18 |
13 |
$0.00 |